scholarly journals Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk

In Vivo ◽  
2020 ◽  
Vol 34 (3) ◽  
pp. 1047-1052
Author(s):  
YU-CHAO LIN ◽  
WEN-SHIN CHANG ◽  
TE-CHUN SHEN ◽  
HSIN-TING LI ◽  
CHIA-HSIANG LI ◽  
...  
2017 ◽  
Vol 42 (2) ◽  
Author(s):  
Meral Yilmaz ◽  
Ayça Tas ◽  
Turgut Kacan ◽  
Musa Sari ◽  
Yavuz Silig

AbstractIntroduction:Association betweenMethods:Total 200 subjects including 100 patients and 100 controls were analyzed and used polymerase chain reaction and restriction fragment length polymorphism methods for genotyping analysis of the polymorphism.Results:We found that smokers compared with non-smokers have approximately eight fold higher lung cancer risk [p=0.0001, OR=8.27 (4.02–16.9)]. Frequency of GG genotype was higher in patients than in controls, but this ratio was not significant (χConclusion:No correlation between


2015 ◽  
Vol 6 (1) ◽  
pp. 91-96
Author(s):  
Xu Wang ◽  
Lina Jin ◽  
Jiuwei Cui ◽  
Kewei Ma ◽  
Xiao Chen ◽  
...  

2019 ◽  
Author(s):  
A Tufman ◽  
S Schneiderbauer ◽  
D Kauffmann-Guerrero ◽  
F Manapov ◽  
C Schneider ◽  
...  

2013 ◽  
Vol 12 (6) ◽  
pp. 1281-1285 ◽  
Author(s):  
Tiberius Dicu ◽  
Doina Todea ◽  
Constantin Cosma ◽  
Loredana Rosca ◽  
Alexandra Cucos Dinu ◽  
...  

2018 ◽  
Vol 238 (5) ◽  
pp. 395-421 ◽  
Author(s):  
Nicolas R. Ziebarth

Abstract This paper empirically investigates biased beliefs about the risks of smoking. First, it confirms the established tendency of people to overestimate the lifetime risk of a smoker to contract lung cancer. In this paper’s survey, almost half of all respondents overestimate this risk. However, 80% underestimate lung cancer deadliness. In reality, less than one in five patients survive five years after a lung cancer diagnosis. Due to the broad underestimation of the lung cancer deadliness, the lifetime risk of a smoker to die of lung cancer is underestimated by almost half of all respondents. Smokers who do not plan to quit are significantly more likely to underestimate this overall mortality risk.


Epigenetics ◽  
2021 ◽  
pp. 1-16
Author(s):  
Marina Laplana ◽  
Matthias Bieg ◽  
Christian Faltus ◽  
Svitlana Melnik ◽  
Olga Bogatyrova ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hui Zeng ◽  
Zhuoyu Yang ◽  
Jiang Li ◽  
Yan Wen ◽  
Zheng Wu ◽  
...  

Abstract Background Published findings suggest sex differences in lung cancer risk and a potential role for sex steroid hormones. Our aim was to perform a meta-analysis to investigate the effects of sex steroid hormone exposure specifically on the risk of lung cancer in women. Methods The PubMed, MEDLINE, Web of Science, and EMBASE databases were searched. The pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) for female lung cancer risk associated with sex steroid hormones were calculated overall and by study design, publication year, population, and smoking status. Sensitivity analysis, publication bias, and subgroup analysis were performed. Results Forty-eight studies published between 1987 and 2019 were included in the study with a total of 31,592 female lung cancer cases and 1,416,320 subjects without lung cancer. Overall, higher levels of sex steroid hormones, both endogenous (OR: 0.92, 95% CI: 0.87–0.98) and exogenous (OR: 0.86, 95% CI: 0.80–0.93), significantly decreased the risk of female lung cancer by 10% (OR: 0.90, 95% CI: 0.86–0.95). The risk of lung cancer decreased more significantly with a higher level of sex steroid hormones in non-smoking women (OR: 0.88, 95% CI: 0.78–0.99) than in smoking women (OR: 0.98, 95% CI: 0.77–1.03), especially in Asia women (OR: 0.84, 95% CI: 0.74–0.96). Conclusions Our meta-analysis reveals an association between higher levels of sex steroid hormone exposure and the decreased risk of female lung cancer. Surveillance of sex steroid hormones might be used for identifying populations at high risk for lung cancer, especially among non-smoking women.


Sign in / Sign up

Export Citation Format

Share Document